Immunologic effects of intermediate-dose IL-2 i.v. after autologous hematopoietic cell transplantation in pediatric solid tumors

Journal of Interferon and Cytokine Research

Volumn 23, Issue 4, 2003, Pages 173-181

  Kalwak, Krzysztof ^a   Ussowicz, Marek ^a   Gorczyńska, Ewa ^a   Turkiewicz, Dominik ^a   Toporski, Jacek ^a   Dobaczewski, Grzegorz ^a   Latos Grazyńska, Elzbieta ^a   Ryczan, Renata ^a   Noworolska Sauren, Dorota ^a   Chybicka, Alicja ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CD3 ANTIGEN; CD56 ANTIGEN; CD57 ANTIGEN; CD8 ANTIGEN; CD94 ANTIGEN; ETOPOSIDE; MELPHALAN; RECOMBINANT INTERLEUKIN 2;

ADOLESCENT; ARTICLE; B LYMPHOCYTE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CHILD; CLINICAL ARTICLE; DOSE RESPONSE; DRUG EFFECT; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; LYMPHOCYTE; MALE; MINIMAL RESIDUAL DISEASE; NATURAL KILLER CELL; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; SOLID TUMOR; TREATMENT OUTCOME;

ADOLESCENT; ANTIGENS, CD; CHILD; CHILD, PRESCHOOL; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HLA-DR ANTIGENS; HUMANS; IMMUNOPHENOTYPING; IMMUNOTHERAPY, ADOPTIVE; INFUSIONS, INTRAVENOUS; INTERLEUKIN-2; KILLER CELLS, NATURAL; LYMPHOCYTE SUBSETS; MALE; NEOPLASMS; PROGNOSIS; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 0037509949     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/107999003765027375     Document Type: Article

References (26)

1. GARAVENTA, A., RONDELLI, R., LANINO, E., DALLORSO, S., DINI, G., BONETTI, F., ARRIGHINI, A., SANTORO, N., ROSSETTI, F., MINIERO, R., ANDOLINA, A., AMICI, A., INDOLFI, P., LO CURTO, M., FAVRE, C., PAOLUCCI, P., PESSION, A., and DE BERNARDI, B. (1996). Myeloablative therapy and bone marrow rescue in advanced neuroblastoma. Report from the Italian Bone Marrow Transplant Registry. Bone Marrow Transplant. 18, 125-130.
2. LADENSTEIN, R., LASSET, C., PINKERTON, R., ZUCKER, J.M., PETERS, C., BURDACH, S., PARDO, N., COZE, C., and DALLORSO, S. (1995). Impact of megatherapy in children with high-risk Ewing's tumours in complete remission: a report from the EBMT Solid Tumour Registry. Bone Marrow Transplant. 15, 697-705.
3. KALWAK, K., GORCZYŃSKA, E., TOPORSKI, J., TURKIEWICZ, D., SLOCIAK, M., USSOWICZ, M., LATOS-GRAŻYŃSKA, E., KRÓL, M., BOGUSLAWSKA-JAWORSKA, J., and CHYBICKA, A. (2002). Immune reconstitution after haematopoietic cell transplantation in children: immunophenotype analysis with regard to factors affecting the speed of recovery. Br. J. Haematol. 118, 74-89.
4. MACKALL, C.L., STEIN, D., FLEISHER, T.A., BROWN, M.R., HAKIM, F.T., BARE, C.V., LEITMAN, S.F., READ, E.J., CARTER, C.S., WEXLER, L.H., and GRESS, R.E. (2000). Prolonged CD4-depletion after sequential autologous peripheral blood progenitor cell infusions in children and young adults. Blood 96, 754-762.
5. PARDO, N., MARTI, F., FRAGA, G., ILLA, J., BADELL, I., PEIRO, M., BERTRAN, E., GARCIA, J., RUEDA, F., and CUBELLS, J. (1996). High-dose systemic interleukin-2 therapy in stage IV neuroblastoma for one year after autologous bone marrow transplantation: pilot study. Med. Pediatr. Oncol. 27, 534-539.
6. PESSION, A., PRETE, A., LOCATELLI, F., PIERINELLI, S., PESSION, A.L., MACCARIO, R., MAGRINI, E., DE BERNARDI, B., PAOLUCCI, P., and PAOLUCCI, G. (1998). Immunotherapy with low-dose recombinant interleukin 2 after high-dose chemotherapy and autologous stem cell transplantation in neuroblastoma. Br. J. Cancer 78, 528-533.
7. TOREN, A., NAGLER, A., ROZENFELD-GRANOT, G., LEVANON, M., DAVIDSON, J., BIELORAI, B., KAPLINSKY, C., MEITAR, D., MANDEL, M., ACKERSTEIN, A., BALLIN, A., ATTIAS, D., BINIAMINOV, M., ROSENTHAL, E., BROKSIMONI, F., RECHAVI, G., and KAUFMANN, Y. (2000). Amplification of immunological functions by subcutaneous injection of intermediate-high dose interleukin-2 for 2 years after autologous stem cell transplantation in children with stage IV neuroblastoma. Transplantation 70, 1100-1104.
8. ATZPODIEN, J., GULATI, S.C., SHIMAZAKI, C., BUHRER, C., OZ, S., KWON, J.H., KOLITZ, J.E., and CLARKSON, B.D. (1988). Ewing's sarcoma: ex vivo sensitivity towards natural and lymphokine-activated killing. Oncology 45, 437-443.
9. GEORGE, R.E., LOUDON, W.G., MOSER, R.P., BRUNER, J.M., STECK, P.A., and GRIMM, E.A. (1988). In vitro cytolysis of primitive neuroectodermal tumors of the posterior fossa (medulloblastoma) by lymphokine-activated killer cells. J. Neurosurg. 69, 403-409.
10. MAIN, E.K., LAMPSON, L.A., HART, M.K., KORNBLUTH, J., and WILSON, D.B. (1985). Human neuroblastoma cell lines are susceptible to lysis by natural killer cells but not by cytotoxic T lymphocytes. J. Immunol. 135, 242-246.
11. BURDACH, S. (1990). Adjuvant Proleukin (rIL-2) in Ewing sarcoma patients with minimal residual disease following bone marrow transplantation. Protocol EC-RM-027, 1-22.
12. KALWAK, K., USSOWICZ, M., GORCZYŃSKA, E., TOPORSKI, J., TURKIEWICZ, D., BOGUSŁAWSKA-JAWORSKA, J., and CHYBICKA, A. (2002). Post-transplant adoptive immunotherapy with interleukin-2 in children suffering from neuroectodermal tumors with poor prognosis. Transplant. Proc. 34, 665-667.
13. KALWAK, K., USSOWICZ, M., TURKIEWICZ, D., RYCZAN, R., KAZANOWSKA, B., GORCZYŃSKA, E., and BOGUSŁAWSKA-JAWORSKA, J. (2000). Clinical use of non-radioactive flow-cytometric natural killer cell cytotoxicity assay in children undergoing bone marrow or peripheral blood progenitor cell transplantation. Centr. Eur. J. Immunol. 25, 52-56.
14. MARTI, F., PARDO, N., PEIRO, M., BERTRAN, E., AMILL, B., GARCIA, J., CUBELLS, J., and RUEDA, F. (1995). Progression of natural immunity during one-year treatment of residual disease in neuroblastoma patients with high doses of interleukin-2 after autologous bone marrow transplantation. Exp. Hematol. 23, 1445-1452.
15. JIANG, Y.Z., BARRETT, A.J., GOLDMAN, J.M., and MAVROUDIS, D.A. (1997). Association of natural killer cell immune recovery with a graft-versus-leukemia effect independent of graft-versus-host disease following allogeneic bone marrow transplantation. Ann. Hematol. 74, 1-6.
16. LOPEZ-JIMENEZ, J., PEREZ-OTEYZA, J., MUNOZ, A., PARRA, C., VILLALON, L., RAMOS, P., MALDONADO, M., GARCIA-LARANA, J., OTHEO, E., ROLDAN, E., GARCIA-AVELLO, A., and ODRIOZOLA, J. (1997). Subcutaneous versus intravenous low-dose IL-2 therapy after autologous transplantation: results of a prospective, non-randomized study. Bone Marrow Transplant. 19, 429-434.
17. + T cells after allogeneic BMT is related with a low incidence of relapse and with cytomegalovirus infection. Br. J. Haematol. 90, 300-307.
18. + cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J. Immunol. 153, 1687-1696.
19. + cell depletion after autologous haematopoietic cell transplantation (AHCT) in children: analysis of factors influencing the immune reconstitution. Bone Marrow Transplant. 29, S48-S49.
20. ZAMBELLO, R., TRENTIN, L., CERUTTI, A., ENTHAMMER, C., MILANI, A., FRANCESCHI, T., MESSINA, C., CETTO, G.L., AGOSTINI, C., and SEMENZATO, G. (1994). Independent expression of p55 and p75 interleukin-2 receptors (IL-2R) during intravenous or subcutaneous administration of recombinant interleukin-2 (rIL-2) by T lymphocytes and natural killer cells. Cancer 74, 2562-2569.
21. WELTE, K., CIOBANU, N., MOORE, M.A.S., GULATI, S., O'REILLY, R.J., and MERTELSMANN, R. (1984). Defective interleukin-2 production in patients after bone marrow transplantation and in vitro restoration of defective T lymphocyte proliferation by highly purified interleukin-2. Blood 64, 380-385.
22. COPER, M.A., FEHNIGER, T.A., and CALIGIURI, M.A. (2001). The biology of human natural killer cells. Trends Immunol. 22, 633-640.
23. VOSS, S.D., DALEY, J., RITZ, J., and ROBERTSON, M.J. (1998). Participation of the CD94 receptor complex in costimulation of human natural killer cells. J. Immunol. 160, 1618-1626.
24. ZINGONI, A., PALMIERI, G., MORRONE, S., CARRETERO, M., LOPEZ-BOTEL, M., PICCOLI, M., FRATI, L., and SANTONI, A. (2000). CD69-triggered ERK activation and functions are negatively regulated by CD94/NKG2-A inhibitory receptor. Eur. J. Immunol. 30, 644-651.
25. BOSLY, A., GUILLAME, T., BRICE, P., HUMBLET, Y., STAQUET, P., DOYEN, C., CHATELAIN, B., FRANKS, C.R., GISSELBRECHT, C., and SYMANN, M. (1992). Effects of escalating doses of recombinant human interleukin-2 in correcting functional T-cell defects following autologous bone marrow transplantation for lymphomas and solid tumors. Exp. Hematol. 20, 962-968.
26. MELONI, G., FOA, R., TOSTI, S., VIGNETTI, M., MANCINI, F., GUARINI, A., MARCHIS, D., GAVOSTO, F., and MANDELLI, F. (1992). Autologous bone marrow transplantation followed by interleukin-2 in children with advanced leukemia: a pilot study. Leukemia 6, 780-785.